CervoMed

Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the top line, reporting zero grant revenue compared to the $50,000 expected. However, the bottom line was better than anticipated, with a GAAP EPS of -$0.868 compared to the -$0.89 consensus, driven by aggressive cost-cutting in R&D and G&A. The company successfully extended its cash runway into Q3 2027 through $20.5M in equity financing, though the strategic focus remains pivoted toward securing a partner for Phase 3 DLB trials.